| Longitudinal analyses reveal immunological misfiring in severe COVID-19 C Lucas, P Wong, J Klein, TBR Castro, J Silva, M Sundaram, ... Nature 584 (7821), 463-469, 2020 | 2124 | 2020 |
| Sex differences in immune responses that underlie COVID-19 disease outcomes T Takahashi, MK Ellingson, P Wong, B Israelow, C Lucas, J Klein, J Silva, ... Nature 588 (7837), 315-320, 2020 | 1488 | 2020 |
| Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2 AL Wyllie, J Fournier, A Casanovas-Massana, M Campbell, M Tokuyama, ... New England Journal of Medicine 383 (13), 1283-1286, 2020 | 977 | 2020 |
| Diverse functional autoantibodies in patients with COVID-19 EY Wang, T Mao, J Klein, Y Dai, JD Huck, JR Jaycox, F Liu, T Zhou, ... Nature 595 (7866), 283-288, 2021 | 910 | 2021 |
| Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT–qPCR primer–probe sets CBF Vogels, AF Brito, AL Wyllie, JR Fauver, IM Ott, CC Kalinich, ... Nature microbiology 5 (10), 1299-1305, 2020 | 806 | 2020 |
| Cigarette smoking and the risk of systemic lupus erythematosus: a meta‐analysis KH Costenbader, DJ Kim, J Peerzada, S Lockman, D Nobles‐Knight, ... Arthritis & Rheumatism 50 (3), 849-857, 2004 | 405 | 2004 |
| Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists J Kim, BT Aftab, JY Tang, DJ Kim, AH Lee, M Rezaee, J Kim, B Chen, ... Cancer cell 23 (1), 23-34, 2013 | 403 | 2013 |
| Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs AL Wyllie, J Fournier, A Casanovas-Massana, M Campbell, M Tokuyama, ... MedRxiv, 2020.04. 16.20067835, 2020 | 393 | 2020 |
| Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma DJ Kim, J Kim, K Spaunhurst, J Montoya, R Khodosh, K Chandra, T Fu, ... Journal of clinical oncology 32 (8), 745-751, 2014 | 331 | 2014 |
| SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity CBF Vogels, AE Watkins, CA Harden, DE Brackney, J Shafer, J Wang, ... Med 2 (3), 263-280. e6, 2021 | 282 | 2021 |
| Delayed production of neutralizing antibodies correlates with fatal COVID-19 C Lucas, J Klein, ME Sundaram, F Liu, P Wong, J Silva, T Mao, JE Oh, ... Nature medicine 27 (7), 1178-1186, 2021 | 248 | 2021 |
| Induction of interferon‐α by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon‐α activity with lung fibrosis D Kim, A Peck, D Santer, P Patole, SM Schwartz, JA Molitor, FC Arnett, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2008 | 195 | 2008 |
| Cutting edge: severe SARS-CoV-2 infection in humans is defined by a shift in the serum lipidome, resulting in dysregulation of eicosanoid immune mediators B Schwarz, L Sharma, L Roberts, X Peng, S Bermejo, I Leighton, ... The Journal of Immunology 206 (2), 329-334, 2021 | 142 | 2021 |
| Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR assays CBF Vogels, AF Brito, AL Wyllie, JR Fauver, IM Ott, CC Kalinich, ... MedRxiv, 2020.03. 30.20048108, 2020 | 105 | 2020 |
| Detection of SARS-CoV-2 RNA by multiplex RT-qPCR E Kudo, B Israelow, CBF Vogels, P Lu, AL Wyllie, M Tokuyama, ... PLoS Biology 18 (10), e3000867, 2020 | 83 | 2020 |
| Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses X Jiang, V Muthusamy, O Fedorova, Y Kong, DJ Kim, M Bosenberg, ... Journal of Experimental Medicine 216 (12), 2854-2868, 2019 | 72 | 2019 |
| Kynurenic acid may underlie sex-specific immune responses to COVID-19 Y Cai, DJ Kim, T Takahashi, DI Broadhurst, H Yan, S Ma, NJW Rattray, ... Science Signaling 14 (690), eabf8483, 2021 | 71 | 2021 |
| Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis W Damsky, A Wang, DJ Kim, BD Young, K Singh, MJ Murphy, J Daccache, ... Nature communications 13 (1), 3140, 2022 | 62 | 2022 |
| Stability of SARS-CoV-2 RNA in nonsupplemented saliva IM Ott, MS Strine, AE Watkins, M Boot, CC Kalinich, CA Harden, ... Emerging infectious diseases 27 (4), 1146, 2021 | 59 | 2021 |
| Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies J Montero, C Gstalder, DJ Kim, D Sadowicz, W Miles, M Manos, ... Nature communications 10 (1), 5157, 2019 | 57 | 2019 |
